How many mutant p53 molecules are needed to inactivate a tetramer?
about
Stxbp4 regulates DeltaNp63 stability by suppression of RACK1-dependent degradationDNA damage in oocytes induces a switch of the quality control factor TAp63α from dimer to tetramerTargeted disruption of transcriptional regulatory function of p53 by a novel efficient method for introducing a decoy oligonucleotide into nuclei.Oncogenic Intra-p53 Family Member Interactions in Human CancersThe Contrived Mutant p53 Oncogene - Beyond Loss of FunctionsThe rebel angel: mutant p53 as the driving oncogene in breast cancer.The p53 circuit boardRadiation-induced cutaneous carcinoma of the head and neck: is there an early role for p53 mutations?p63 promotes cell survival through fatty acid synthasecDNA sequencing improves the detection of P53 missense mutations in colorectal cancerRadiosensitization of prostate cancer by priming the wild-type p53-dependent cellular senescence pathway.Limited importance of the dominant-negative effect of TP53 missense mutationsTracing the protectors path from the germ line to the genome.The role of mutant p53 in human cancer.An Integrated Genetic-Genomic Approach for the Identification of Novel Cancer Loci in Mice Sensitized to c-Myc-Induced Apoptosis.PIN3 duplication may be partially responsible for TP53 haploinsufficiencyp53 acts as a co-repressor to regulate keratin 14 expression during epidermal cell differentiationOnly missense mutations affecting the DNA binding domain of p53 influence outcomes in patients with breast carcinoma.Structure-based predictions broadly link transcription factor mutations to gene expression changes in cancers.Effects of Δ40p53, an isoform of p53 lacking the N-terminus, on transactivation capacity of the tumor suppressor protein p53.Re-engineered p53 activates apoptosis in vivo and causes primary tumor regression in a dominant negative breast cancer xenograft model.Translational approaches targeting the p53 pathway for anti-cancer therapy.The p63/p73 network mediates chemosensitivity to cisplatin in a biologically defined subset of primary breast cancersCleavage of the transactivation-inhibitory domain of p63 by caspases enhances apoptosis.Post-translational modification of p53 in tumorigenesis.Mutant p53: one name, many proteins.Gender specific association of TP53 polymorphisms (EX4 215G>C Arg72Pro, IVS3+40-41ins16, and IVS6+62G>A), with risk of oral cancer subtypes and overall survival of the patients.Probing potential binding modes of the p53 tetramer to DNA based on the symmetries encoded in p53 response elements.Elimination of wild-type P53 mRNA in glioblastomas showing heterozygous mutations of P53.ΔNp63α utilizes multiple mechanisms to repress transcription in squamous cell carcinoma cells.Allele-specific silencing of mutant p53 attenuates dominant-negative and gain-of-function activities.p53-independent mechanisms regulate the P2-MDM2 promoter in adult astrocytic tumoursTargeting prostate cancer based on signal transduction and cell cycle pathways.DEK proto-oncogene expression interferes with the normal epithelial differentiation program.Versatile functions of p53 protein in multicellular organismsΔNp63 mediates cellular survival and metastasis in canine osteosarcomaThe tumor suppressor p53: from structures to drug discovery.The aggregation of mutant p53 produces prion-like properties in cancer.The clinical development of p53-reactivating drugs in sarcomas - charting future therapeutic approaches and understanding the clinical molecular toxicology of Nutlins.Alterations of p63 and p73 in human cancers.
P2860
Q24311751-C8E3E90F-3EAE-4FF3-AD20-CA6682812CA5Q24600818-4B2485BA-304D-4BE1-82BF-160FA6458CC1Q24810050-095C8A1C-93D4-4905-A390-8CED9D099B97Q26749382-CCC47474-A8C1-40AA-A3A3-7AC7F1C65475Q26772237-E3B9D836-301B-4B55-B1A4-BB7AF8DDE460Q27686765-C2B7F28F-50A8-49F7-A7CD-613F7F3F1051Q28259725-9A8E93D1-6CA8-4EBA-8B0D-C9D48FDA1B28Q33249067-46355473-F3CA-4B7D-8859-C82475DF9354Q33466069-D65DED9E-803F-4D73-AF22-A5C6938B97F6Q33492556-7FA34435-95E8-4172-8763-265D7C43E790Q33926909-A7775720-2C48-43CF-9EC9-85BDFC5BC8EAQ33931015-2858B555-FD14-46DA-ABC3-D22463D034D8Q34100529-4AAC04EB-A7E3-45E7-AC08-1E39F0EEE7BEQ34153014-7DABD7DD-0E48-4CDC-8E34-61150B622F36Q34171480-3F158A15-C5FD-4C39-873B-92E3DC3691FFQ34252210-9ADCE0DA-8E9C-46DE-98A1-CAEF8297CD30Q34388165-2EB18A3D-7CB9-499B-B4CA-C93B231A1E6CQ34566248-D18C2FF6-B93C-4C06-BC16-9AAF21A40416Q34579681-B3D945F6-0F77-4921-9345-E5D45A3AC90BQ34628519-1768C8D5-79E6-481C-A414-F3A1162597A7Q35073239-0CA17533-A853-4043-911B-946E686D2C72Q35708113-B49A5837-879A-4400-84FC-495428CFE674Q35745252-D8A2BA8A-15B2-4302-B9B1-E1D41773947AQ35864969-91A27766-638E-4A1D-B2FC-E5476C45C4E4Q35930703-57F1AF6B-B029-40E5-B4CB-CF5B38375B10Q36070574-AA8DAC3D-4ED2-4386-A5CA-252FE4AACB21Q36105663-DC50C6DC-5FAA-4B4A-ABBC-E2DE9183C1A5Q36360657-04631EE8-1484-4B66-993B-7446F1FFCCD1Q36615676-4CDA07B8-1E16-49D0-A882-855C14F7D34CQ36654367-6AF55FA0-9086-434A-BFF0-38D8AF370E61Q36905671-138F4EB0-9481-4145-95B7-A356A255244DQ36935974-14FF9072-3BB4-44FB-831D-B2566B404FB7Q36995054-796CA8D5-BC0F-4C2F-AF8B-0FF422E31273Q37073767-727658BD-232C-488D-834A-E8ABE1C09508Q37087404-8935892C-1B18-408E-BDA4-6450AA1B58A2Q37565526-D0E2800A-316E-444E-93AC-A86D8BC29370Q37762069-8F5ABAD9-6BC2-431B-8A3E-0DBCB6764C6FQ38186535-75A72025-1FB1-4C79-B2CF-846424DD1F91Q38192005-3BED7195-C159-4E98-BBB2-728D6E24AC68Q38247152-D68850EA-CADA-4197-A88D-E61FFA0FE87D
P2860
How many mutant p53 molecules are needed to inactivate a tetramer?
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on April 2004
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
How many mutant p53 molecules are needed to inactivate a tetramer?
@en
How many mutant p53 molecules are needed to inactivate a tetramer?
@nl
type
label
How many mutant p53 molecules are needed to inactivate a tetramer?
@en
How many mutant p53 molecules are needed to inactivate a tetramer?
@nl
prefLabel
How many mutant p53 molecules are needed to inactivate a tetramer?
@en
How many mutant p53 molecules are needed to inactivate a tetramer?
@nl
P2093
P2860
P1476
How many mutant p53 molecules are needed to inactivate a tetramer?
@en
P2093
Wai Yi Siu
Wan Mui Chan
P2860
P304
P356
10.1128/MCB.24.8.3536-3551.2004
P407
P50
P577
2004-04-01T00:00:00Z